

1 **Title: Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse**  
2 **Population in the United States**

3  
4 **Authors:** Kaitlin Rainwater-Lovett<sup>1,2</sup>, John T. Redd<sup>2</sup>, Miles A. Stewart<sup>1,2</sup>, Natalia Elías Calles<sup>3</sup>, Tyler  
5 Cluff<sup>3</sup>, Mike Fang<sup>1</sup>, Mark J. Panaggio<sup>1</sup>, Anastasia S. Lambrou<sup>1,2</sup>, Jonathan K. Thornhill<sup>1,2</sup>, Christopher  
6 Bradburne<sup>1,4</sup>, Samuel Imbriale<sup>2</sup>, Jeffrey D. Freeman<sup>1,2</sup>, Michael Anderson<sup>2</sup>, Robert Kadlec<sup>2</sup>

7  
8 **Affiliations:** <sup>1</sup>Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory,  
9 Laurel, Maryland; <sup>2</sup>Office of the Assistant Secretary for Preparedness and Response, U.S. Department of  
10 Health and Human Services, Washington, DC; <sup>3</sup>Tucson Medical Center, TMC HealthCare, Tucson,  
11 Arizona; <sup>4</sup>McKusick-Nathans Department of Genetic Medicine, Johns Hopkins School of Medicine,  
12 Baltimore, Maryland.

13  
14  
15 **Keywords:** Monoclonal antibody; bamlanivimab; SARS-CoV-2; COVID-19; emergency response

16  
17 **Running Title:** Monoclonal Antibodies in COVID Patients

18  
19 **Corresponding Author:** Kaitlin Rainwater-Lovett, PhD, MPH; Kaitlin.Lovett@jhuapl.edu

20  
21 **Alternate Corresponding Author:** John T. Redd, MD, MPH; John.Redd@hhs.gov

22  
23 **Summary:** In a diverse, real-world COVID-19 patient population, treatment with monoclonal antibodies  
24 significantly decreased the risk of subsequent emergency department visit or hospitalization within 30  
25 days of a positive SARS-CoV-2 viral test.

26

27 **ABSTRACT**

28 **Background:** Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for  
29 limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains  
30 limited, particularly in disadvantaged populations.

31  
32 **Methods:** Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center  
33 in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department  
34 of Health and Human Services' National Disaster Medical System. Patients who received mAbs were  
35 compared to untreated patients from the time period before mAb availability who met eligibility criteria  
36 for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of  
37 hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19.

38  
39 **Results:** Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated.  
40 Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%)  
41 presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared  
42 to 39/328 (12%) untreated patients ( $p < 0.001$ ). After adjusting for age, gender, and comorbidities, the risk  
43 of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients  
44 (95% confidence interval [CI]: 66%-94%).

45  
46 **Conclusions:** In this diverse, real-world COVID-19 patient population, mAb treatment significantly  
47 decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in  
48 disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all  
49 populations in the United States to ensure health equity.

## 50 **BACKGROUND**

51 In late 2019, a new respiratory infection was detected in China and alarmed global health experts with its  
52 growing case incidence and clinical severity [1,2]. Over the course of a few months, severe acute  
53 respiratory syndrome-coronavirus-2 (SARS-CoV-2) spread around the world, overwhelming health  
54 systems. While a substantial proportion of patients remain asymptomatic [3], coronavirus disease 2019  
55 (COVID-19) can rapidly progress and require hospitalization and intensive care. Severe disease is  
56 associated with older age, obesity, and several chronic medical conditions including cardiovascular,  
57 kidney, and pulmonary comorbidities [4–7].

58  
59 As of late January 2021, approximately 15,000 new COVID-19 hospital admissions were occurring per  
60 day in the United States (U.S.) and hospital bed capacity exceeded 72% [8,9]. As healthcare systems  
61 continued to approach maximum bed capacity, a critical need for therapeutic interventions to reduce  
62 COVID-related hospitalizations emerged. Although therapeutic options for COVID-19 remain limited,  
63 monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 are a promising treatment for limiting the  
64 progression of disease. Four mAbs are available in the U.S. through Emergency Use Authorizations  
65 (EUAs) by the U.S. Food and Drug Administration (FDA): bamlanivimab monotherapy [10],  
66 bamlanivimab in combination with etesevimab [11], and casirivimab in combination with imdevimab  
67 [12]. These products are human IgG1 antibodies that neutralize the virus by binding the spike protein of  
68 SARS-CoV-2, preventing attachment of the virus to the human cellular receptor angiotensin-converting  
69 enzyme-2. A single infusion of bamlanivimab was recently demonstrated to reduce the risk of  
70 hospitalization, emergency department (E.D.) visits, and death among patients with mild to moderate  
71 COVID symptoms in randomized, controlled phase 2/3 trials by more than 70% [10].

72  
73 Monoclonal antibodies are underutilized as a treatment for reducing severe disease and could significantly  
74 decrease hospitalizations and potentially long-term COVID effects [13]. Utilization can be particularly  
75 challenging in racial and ethnic minorities and disadvantaged populations, in whom prevalence of risk

76 factors for COVID-19 progression and death may be higher. A recent review highlights racial and ethnic  
77 minorities are commonly employed in jobs that require in-person presence that increase exposure to  
78 SARS-CoV-2, language barriers that limit understanding of public health information, and poorer access  
79 to health care facilities [14]. These factors can delay treatment until patients are in a critical state, which  
80 can shorten the therapeutic window for effective mAb receipt or possibly preclude mAb use entirely.  
81 Thus, mAb may be particularly underutilized in precisely the populations that would have the greatest  
82 benefit, threatening to exacerbate existing health inequities in the United States. Two primary barriers to  
83 implementation of mAb infusion therapy at healthcare facilities are: 1) a limited understanding of the  
84 necessary resources and processes to mobilize infusion sites, and 2) understanding the magnitude of the  
85 potential impact of mAb treatment on reducing the severity of disease. We previously addressed the first  
86 barrier through a process assessment and improvement analysis [15], demonstrating considerable  
87 flexibility in assembling an infusion site and the feasibility of mAb delivery in diverse treatment  
88 locations. Here, we aim to determine the extent to which mAb treatment decreases COVID-related  
89 hospital admission and E.D. visits among patients with mild to moderate COVID-19 within 30 days of  
90 treatment in the U.S.

91

## 92 **METHODS**

93 We conducted a retrospective cohort study in February 2021 of SARS-CoV-2-positive patients to  
94 evaluate the effect of mAb treatment on the risk of a medical visit within 30 days. This study evaluated  
95 patients who presented to a single medical center to which the U.S. Department of Health and Human  
96 Services' Assistant Secretary for Preparedness and Response (ASPR) had deployed elements of the  
97 National Disaster Medical System (NDMS) to establish a mAb infusion site. This medical center is  
98 located in a moderately sized city with a population of approximately 500,000. The city's population is  
99 56.4% non-White with a median household income that is 64% of the U.S. level and a poverty rate of  
100 23.4% [16,17]. This clinical support activity was conducted as part of the ASPR public health response to  
101 the COVID-19 pandemic and at the request of the host medical center. Under HHS Office of Health

102 Research Protection guidelines, it was judged a non-research COVID-19 response [18]. The Johns  
103 Hopkins University Applied Physics Laboratory and the medical center concurred with a non-research  
104 determination.

105  
106 The target population for this evaluation was patients with positive results of SARS-CoV-2 viral testing  
107 who were 12 years of age or older, at least 40 kg in weight, and at high risk for progressing to severe  
108 COVID-19 or hospitalization. Clinical data were obtained in February 2021 from electronic health  
109 records maintained by the medical system, which includes both a major medical center and several  
110 outpatient clinics with integrated health records.

111  
112 Our retrospective cohort consisted of patients presenting to either outpatient clinics or the medical center  
113 who tested positive for SARS-CoV-2 via an antigen or polymerase chain reaction-based test. Patients  
114 with positive viral test results recorded in the electronic health record between July 1<sup>st</sup> and December 20<sup>th</sup>,  
115 2020 were identified as untreated patients. These patients were eligible for inclusion in the analysis if they  
116 met the eligibility criteria for mAb treatment (Table 1). Treatment with mAb became available at the  
117 medical center on January 7<sup>th</sup>, 2021. SARS-CoV-2 patients who received mAb infusions between  
118 January 7<sup>th</sup> and January 15<sup>th</sup>, 2021, are referred to as treated patients. We selected the test date of  
119 December 20<sup>th</sup>, 2020, as the final date of eligibility for untreated patients to ensure no overlap in the  
120 treated and untreated patient populations based on the maximum ten-day symptom onset window  
121 permitting mAb treatment eligibility and decreased healthcare seeking behavior during winter holidays  
122 [19]. The decision to seek mAb treatment for COVID-19 was made by the patient and the provider. At  
123 presentation for mAb treatment, the date of SARS-CoV-2 test positivity was confirmed through paper  
124 records provided by the patient or rapid antigen test performed on-site, and intake staff collected  
125 demographic and clinical information, including eligibility criteria for treatment (Table 1). Any adverse  
126 events were recorded on patient forms. While mAb treatments continued after January 15<sup>th</sup>, the end date  
127 was established to permit sufficient follow-up at the time of data collection.

128

129 Data extracted from existing medical records included age, sex, race, ethnicity, height and weight, and  
130 presence of the following pre-existing conditions as recorded by clinicians in the health record: blood  
131 disorders (e.g., sickle cell disease, thalassemia), cancer, diabetes, Down syndrome, chronic lung disease,  
132 chronic liver disease, hypertension, immunosuppressive condition, chronic kidney disease, obesity or  
133 overweight, and organ transplant. Pre-existing conditions were captured from the Chief Complaint of  
134 health records within the six months prior to the date of SARS-CoV-2 testing. Laboratory values and  
135 clinical exam measurements were not extracted to define pre-existing conditions.

136

137 Race categories were defined as American Indian/Alaskan Native, Asian, Black, Hawaiian/Pacific  
138 Islander, White, and other. Ethnicity was defined as Hispanic or Non-Hispanic. Body mass index (BMI)  
139 was calculated as kilograms per meter-squared. In the absence of height and weight, the pre-existing  
140 conditions of “obesity” and “overweight” were used for BMI categorization. The composite outcome of a  
141 medical visit was defined as the first instance of COVID-19-related E.D. visit or hospitalization after  
142 positive SARS-CoV-2 viral test result and was obtained from the electronic health record. A medical visit  
143 was COVID-related if one or more of the following chief complaints were identified: blood in sputum,  
144 chest congestion, chest pain, cough, COVID-19 screening, difficulty breathing, fever, flu-like symptoms,  
145 hypoxia, shortness of breath, sore throat, or weakness [20–23]. Dates of COVID-19 symptom onset and  
146 positive SARS-CoV-2 antigen test results performed at the infusion center were recorded on paper-based  
147 forms upon arrival of patients for mAb treatment, but were not recorded in electronic health records.

148

149 Characteristics of patients were compared using Welch t-tests for continuous variables and Chi-squared  
150 test for categorical variables. Age was categorized as younger than or equal to 65 years of age or older  
151 than 65 years. Logistic regression was used to evaluate the effect of mAb treatment on medical visits that  
152 occurred within 30 days of SARS-CoV-2-positive viral test by applying a generalized linear model with a  
153 logits link function. The occurrence of a medical visit was evaluated as a binary outcome. Variables

154 included in the model were those deemed epidemiologically relevant. Model diagnostics indicated that no  
155 data points substantially influenced model estimates, as assessed by Cook's distance. All data processing  
156 and analyses were conducted using R version 4.0.3 [24].

157

## 158 **RESULTS**

159 Medical records were available from 875 SARS-CoV-2-positive patients (Table 2) confirmed during July  
160 1 through December 20, 2020. Of these, 547 patients did not meet eligibility criteria for mAb treatment  
161 (Table 1). This resulted in the analysis of 598 patients, 270 of whom (45%) were eligible for and received  
162 bamlanivimab during a single week in January 2021, comprising the treated group. A total of 328  
163 untreated patients (55%) served as the historical comparator population. These untreated patients  
164 represented individuals who would have been eligible for mAb infusion had the treatment been available  
165 at the time of their COVID-19-positive viral test results.

166

167 Among the 598 patients, no statistically significant differences in sex or ethnicity were identified between  
168 the treated and untreated study groups (Table 2). Untreated patients were an average of three years  
169 younger than the treated patients ( $p=0.02$ ), and health records were more likely to report untreated  
170 patients as overweight or obese and with a history of hypertension or cardiovascular disease (all  $p<0.001$ ).

171

172 In the 30 days following a positive SARS-CoV-2 test result, five of 270 treated patients (1.9%) presented  
173 to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test result, compared to  
174 39 of the 328 untreated patients (12%) ( $p<0.01$ ) (Table 2). Untreated patients had a medical visit a median  
175 of four days after SARS-CoV-2-positive viral test result (interquartile range [IQR]: 2, 8 days), while  
176 treated patients had a medical visit an average of eight days after mAb treatment (IQR: 4, 8) ( $p=0.112$  by  
177 Kolmogorov-Smirnov test). No adverse events were reported among mAb-infused patients.

178

179 Treatment with mAb was associated with an 82% decrease in the risk of a COVID-19-related medical  
180 visit within 30 days of a positive SARS-CoV-2 viral test after adjusting for demographic factors and pre-  
181 existing conditions (95% CI: 66%, 94%) (Table 3). A BMI  $\geq 35$  greatly increased the risk of a medical  
182 visit in the multivariable analysis (odds ratio: 6.44 [95% CI: 2.48, 16.71]). Age  $\geq 65$  was also associated  
183 with a 2.10-fold increased risk but this was not statistically significant (95% CI: 0.97, 4.77).

184

## 185 **DISCUSSION**

186 This study demonstrated that a single infusion of bamlanivimab within 10 days of COVID-19 symptom  
187 onset decreased the risk of COVID-related hospitalization and E.D. visits among a real-world, diverse  
188 patient population in the U.S. who were at risk of progression to severe disease compared with an  
189 historical untreated population. The association between treatment and improved clinical outcome  
190 remained significant after controlling for gender, age, race, ethnicity, and pre-existing conditions. A BMI  
191 of greater than 35 remained highly associated with disease progression requiring a medical visit after  
192 adjusting for mAb treatment and other co-factors.

193

194 Approximately 2% of the treated group were hospitalized or visited the E.D. after mAb infusion, which  
195 was similar to the rate of medical visits in the efficacy assessment of bamlanivimab [10]. In contrast,  
196 almost 12% of untreated patients in the current study required a medical visit within 30 days of a positive  
197 COVID test. This risk was nearly double the 6.3% of placebo controls who presented to the E.D., required  
198 hospitalization, or died in the Phase 2/3 trial [10], suggesting that the current study's patient population  
199 was older and had a higher risk of progression to severe disease. This difference reinforces the need to  
200 evaluate therapeutics in diverse populations and in real-world clinical situations, as patients who are  
201 referred for and receive treatments often differ from those who are enrolled in a clinical trial.

202

203 Few treatment options have been available during the COVID-19 pandemic for reducing the severity of  
204 disease and preventing hospitalization, leading to significant strain on many hospitals[8]. Reducing the



205 proportion of patients who progress to severe disease and require hospitalization by approximately 80%  
206 would be of immense value to medical centers, in which intensive care units contain an average of only  
207 15 staffed beds [25]. The availability of mAbs at no drug cost due to their procurement by the U.S.  
208 government places a therapeutic option more easily within reach of many who are at the highest risk of  
209 severe disease.

210  
211 The use of electronic health records is a strength of the current study. Due to the medical center's  
212 electronic record system, we were able to assemble a SARS-CoV-2-positive cohort who would have been  
213 eligible for mAb treatment at the time of their diagnosis based on pre-existing risk factors, had the  
214 therapeutics been available at that time. An additional strength of this study was the diverse patient  
215 population in the area, resulting in the inclusion of a large proportion of patients of Hispanic ethnicity  
216 (39%). Our results are consistent with prior clinical trial data showing a 70% reduction in medical visits  
217 by mAb-infused patients compared to placebo controls[10]. A BMI of 35 or higher was a strong  
218 independent predictor of an increased risk of medical visits, which was consistent with other COVID-19  
219 studies [7].

220  
221 A significantly larger proportion of untreated patients had co-morbidities that increase the risk of severe  
222 COVID-19 outcomes compared to treated patients in the current study, notably a higher proportion with  
223 elevated BMI. Although mAb treatment remained significantly associated with a decreased risk of  
224 hospitalization or E.D. visit after adjusting for pre-existing conditions (82% reduction; 95% CI: 66%,  
225 94%), the baseline differences between the treated and untreated groups suggest a potential difference in  
226 accessibility of mAb treatment. For example, patients with fewer co-morbidities may have more easily  
227 been able to avail themselves of treatment. The continued U.S. government efforts to increase access to  
228 mAbs are intended to ensure that COVID-19 therapeutics are equally available to all patients - an  
229 important national health equity consideration.

230

231 To receive mAb infusions, patients must seek out treatment within 10 days of a positive SARS-CoV-2  
232 antigen test result. This can be burdensome and stresses the importance of widespread availability of  
233 testing. Evidence also suggests that patients with more significant or severe co-morbidities are likely to  
234 have more complete health records [26,27]. This effect may have overrepresented patients with more  
235 severe chronic conditions into the untreated group based on the application of mAb eligibility criteria for  
236 inclusion in the analysis. Additionally, without active follow-up of patient outcomes, misclassification of  
237 the medical visit outcome was possible as patients could seek follow-up care at any facility. These  
238 considerations and the differences between the study groups suggest confounders remain that were  
239 unmeasured in this analysis and may reflect the retrospective untreated population group in the study's  
240 design. These limitations could be further evaluated in a larger, prospective, observational study.

241  
242 While individuals at increased risk of SARS-CoV-2 infection and severe disease are prioritized for  
243 vaccination in most U.S. states, therapeutic options such as mAb infusions remain a necessity for those  
244 who remain unvaccinated due to contraindications or vaccine hesitancy [28,29]. Although viral variants  
245 are being discovered that are poorly neutralized by several mAbs in laboratory studies [30,31], suggesting  
246 reduced effectiveness in patient populations, relatively minor adjustments to the currently available mAb  
247 products can counter these changes. Additionally, the FDA has issued guidance encouraging use of  
248 existing formulations, platforms, and clinical protocols to facilitate expedited review and rapid  
249 introduction of these modified mAb products to general public [32].

250  
251 In summary, we demonstrated that mAb treatment with bamlanivimab was associated with an  
252 approximately 80% reduction in the risk of medical visits among a diverse COVID-19 patient population  
253 under real-world conditions. Increasing availability and utilization of novel COVID-19 therapeutics may  
254 improve patient outcomes, reduce burden on the health system, and contribute to increased health equity  
255 in the United States.

256

257 **FUNDING AND CONFLICT OF INTEREST STATEMENT**

258 All authors have completed the ICMJE uniform disclosure form: all authors had financial support from  
259 the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness  
260 and Response for the submitted work; no financial relationships with any organizations that might have  
261 an interest in the submitted work in the previous three years; no other relationships or activities that could  
262 appear to have influenced the submitted work.

263

264 **ACKNOWLEDGEMENTS**

265 The authors acknowledge the significant efforts of George (Mark) Thorp, RN, EMT-P, who led and  
266 coordinated the Disaster Medical Assistance Team's mAb infusion site set-up, initiation, and integration  
267 with the Tucson Medical Center. The authors thank David W. Forest, Christopher Florko, and Judy  
268 McCord from TMC Health Care, who provided extensive time and support for this analysis.

269

270 **REFERENCES**

- 271 1. ProMed-mail. Undiagnosed pneumonia - China (Hubei) Request for Information. 2019. Available  
272 at: <http://www.promedmail.org>. Accessed 1 February 2021.
- 273 2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease  
274 2019 (COVID-19) Outbreak in China. *JAMA* **2020**; 323:1239. Available at:  
275 <https://jamanetwork.com/journals/jama/fullarticle/2762130>.
- 276 3. Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among  
277 COVID-19 positive persons and their transmission potential: A systematic review and meta-  
278 analysis. *PLoS One* **2020**; 15:e0241536. Available at:  
279 <https://dx.plos.org/10.1371/journal.pone.0241536>.
- 280 4. Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. *Epidemiol  
281 Infect* **2020**; 148:e175. Available at:  
282 [https://www.cambridge.org/core/product/identifier/S095026882000179X/type/journal\\_article](https://www.cambridge.org/core/product/identifier/S095026882000179X/type/journal_article).
- 283 5. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019  
284 (COVID-19) infection. *Int Urol Nephrol* **2020**; 52:1193–1194. Available at:  
285 <http://link.springer.com/10.1007/s11255-020-02451-9>.
- 286 6. Oetjens MT, Luo JZ, Chang A, et al. Electronic health record analysis identifies kidney disease as  
287 the leading risk factor for hospitalization in confirmed COVID-19 patients. *PLoS One* **2020**;  
288 15:e0242182. Available at: <https://dx.plos.org/10.1371/journal.pone.0242182>.
- 289 7. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19–Related  
290 Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death —  
291 United States, March–December 2020. *MMWR Morb Mortal Wkly Rep* **2021**; 70:355–361.  
292 Available at: [http://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s\\_cid=mm7010e4\\_w](http://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s_cid=mm7010e4_w).
- 293 8. U.S. Interagency Data Strategy and Execution Working Group. Community Profile Reports. 2021.  
294 Available at: [https://beta.healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-  
295 d9w9](https://beta.healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-d9w9). Accessed 14 March 2021.


- 296 9. U.S. Department of Health and Human Services. COVID-19 Reported Patient Impact and Hospital  
297 Capacity by State Timeseries. 2021. Available at: [https://healthdata.gov/Hospital/COVID-19-](https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh)  
298 [Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh](https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh). Accessed 1 February 2021.
- 299 10. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients  
300 with Covid-19. *N Engl J Med* **2021**; 384:229–237. Available at:  
301 <http://www.nejm.org/doi/10.1056/NEJMoa2029849>.
- 302 11. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination  
303 With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. *JAMA* **2021**;  
304 325:632. Available at: <https://jamanetwork.com/journals/jama/fullarticle/2775647>.
- 305 12. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody  
306 Cocktail, in Outpatients with Covid-19. *N Engl J Med* **2021**; 384:238–251. Available at:  
307 <http://www.nejm.org/doi/10.1056/NEJMoa2035002>.
- 308 13. The National Academies of Sciences Engineering and Medicine. Rapid Expert Consultation on  
309 Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January  
310 29, 2021). Washington, D.C.: National Academies Press, 2021. Available at:  
311 <https://www.nap.edu/catalog/26063>.
- 312 14. Lopez L, Hart LH, Katz MH. Racial and Ethnic Health Disparities Related to COVID-19. *JAMA*  
313 **2021**; 325:719. Available at: <https://jamanetwork.com/journals/jama/fullarticle/2775687>.
- 314 15. Lambrou A, Stewart M, Rainwater-Lovett K, et al. Implementation of SARS-CoV-2 monoclonal  
315 antibody infusion sites at three medical centers in the United States: Strengths and challenges to  
316 inform COVID-19 pandemic and future public health emergency use. (Manuscript In Progress)  
317 **2021**
- 318 16. Data USA. Tucson, AZ. 2018. Available at: <https://datausa.io/profile/geo/tucson-az/>. Accessed 21  
319 March 2021.
- 320 17. U.S. Census Bureau. Income and Poverty in the United States: 2019. 2020. Available at:  
321 <https://www.census.gov/library/publications/2020/demo/p60-270.html>.

- 322 18. U.S. Department of Health and Human Services. Research Guidance on Coronavirus. 2020.  
323 Available at: [https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-](https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-19/index.html)  
324 [19/index.html](https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-19/index.html). Accessed 7 January 2021.
- 325 19. Ewing A, Lee EC, Viboud C, Bansal S. Contact, travel, and transmission: The impact of winter  
326 holidays on influenza dynamics in the United States. *J Infect Dis* **2016**; :jiw642. Available at:  
327 <https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiw642>.
- 328 20. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict  
329 potential COVID-19. *Nat Med* **2020**; 26:1037–1040. Available at:  
330 <http://www.nature.com/articles/s41591-020-0916-2>.
- 331 21. Clifford CT, Pour TR, Freeman R, et al. Association between COVID-19 diagnosis and presenting  
332 chief complaint from New York City triage data. *Am J Emerg Med* **2020**; Available at:  
333 <https://linkinghub.elsevier.com/retrieve/pii/S0735675720309864>.
- 334 22. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in  
335 primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database Syst Rev*  
336 **2020**; Available at: <http://doi.wiley.com/10.1002/14651858.CD013665>.
- 337 23. Perotte R, Sugalski G, Underwood JP, Ullo M. Characterizing COVID-19: A chief complaint  
338 based approach. *Am J Emerg Med* **2020**; Available at:  
339 <https://linkinghub.elsevier.com/retrieve/pii/S0735675720308135>.
- 340 24. R Core Team. R: A language and environment for statistical computing. 2017; Available at:  
341 <https://www.r-project.org/>.
- 342 25. U.S. Department of Health and Human Services. Intensive Care Unit Bed Utilization by State.  
343 2021. Available at: <https://protect-public.hhs.gov/pages/hospital-utilization>. Accessed 14 March  
344 2021.
- 345 26. Wang EC-H, Wright A. Characterizing outpatient problem list completeness and duplications in  
346 the electronic health record. *J Am Med Informatics Assoc* **2020**; 27:1190–1197. Available at:  
347 <https://academic.oup.com/jamia/article/27/8/1190/5867232>.

- 348 27. Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness  
349 of electronic health records. *AMIA . Annu Symp proceedings AMIA Symp* **2013**; 2013:1472–7.  
350 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24551421>.
- 351 28. Kaiser Family Foundation. COVID-19 Vaccine Hesitancy: Trends, Reasons, and Subgroups. 2020.  
352 Available at: [https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-](https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/)  
353 [december-2020/](https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/). Accessed 15 March 2021.
- 354 29. Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and  
355 Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States,  
356 September and December 2020. *MMWR Morb Mortal Wkly Rep* **2021**; 70:217–222. Available at:  
357 [http://www.cdc.gov/mmwr/volumes/70/wr/mm7006e3.htm?s\\_cid=mm7006e3\\_w](http://www.cdc.gov/mmwr/volumes/70/wr/mm7006e3.htm?s_cid=mm7006e3_w).
- 358 30. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and  
359 B.1.1.7. *Nature* **2021**; Available at: <http://www.nature.com/articles/s41586-021-03398-2>.
- 360 31. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by  
361 monoclonal and serum-derived polyclonal antibodies. *Nat Med* **2021**; Available at:  
362 <http://www.nature.com/articles/s41591-021-01294-w>.
- 363 32. US Department of Health and Human Services Food and Drug Administration Center for Drug  
364 Evaluation and Research. Development of Monoclonal Antibody Products Targeting SARS-CoV-  
365 2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health  
366 Emergency: Guidance for Industry. 2021. Available at: [https://www.fda.gov/regulatory-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-including-addressing-impact-emerging)  
367 [information/search-fda-guidance-documents/development-monoclonal-antibody-products-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-including-addressing-impact-emerging)  
368 [targeting-sars-cov-2-including-addressing-impact-emerging](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-including-addressing-impact-emerging). Accessed 17 March 2021.
- 369 33. U.S. Centers for Disease Control and Prevention National Center for Health Statistics. Clinical  
370 Growth Charts. 2017. Available at: [https://www.cdc.gov/growthcharts/clinical\\_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm).  
371 Accessed 1 February 2021.
- 372

373 **FIGURES AND TABLES**

374 **Figure 1.** Flow diagram applying the inclusion criteria to collected health records that  
375 generated the final study population.



376



377

378 **Table 1.** *Eligibility criteria for SARS-CoV-2 monoclonal antibody infusions.*

---

**Inclusion Criteria**

---

Laboratory-confirmed COVID-19 (documented positive COVID-19 viral test result)

Symptom onset within the last ten days

≥12 years of age and weight ≥40 kilograms

Plus, at least ONE of the following risk factors:

- Body mass index ≥ 35
  - Chronic kidney disease
  - Diabetes mellitus
  - Immunosuppressive disease
  - Currently receiving immunosuppressive treatment
  - ≥ 65 years of age
  - ≥ 55 years of age AND:
    - o Cardiovascular disease, or
    - o Hypertension, or
    - o Chronic pulmonary obstructive disease/other chronic respiratory disease
  - 12 – 17 years of age AND:
    - o BMI ≥ 85<sup>th</sup> percentile for age and gender based on Centers for Disease Control and Prevention’s growth charts[33], or
    - o Sickle cell disease, or
    - o Congenital or acquired heart disease, or
    - o Neurodevelopmental disorders (e.g., cerebral palsy), or
    - o A medically-related technological dependence (e.g., tracheostomy, gastrostomy, positive pressure ventilation unrelated to COVID-19), or
    - o Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control.
- 

379

380

381 **Table 2. Baseline demographic and medical characteristics of SARS-CoV-2-positive patients.**

382 *Abbreviations: Max, maximum; Min, minimum; SD, standard deviation.*

	<b>Untreated (N=328)</b>	<b>mAB Treated (N=270)</b>	<b>Overall (N=598)</b>	<b>P-value</b>
<b>Sex</b>				0.10
Female	211 (64.3%)	155 (57.4%)	366 (61.2%)	
Male	117 (35.7%)	115 (42.6%)	232 (38.8%)	
<b>Age</b>				0.03
Mean (SD)	61.0 (17.8)	63.9 (15.9)	62.3 (17.0)	
Median [Min, Max]	65.0 [13.0, 98.0]	66.0 [18.0, 98.0]	65.0 [13.0, 98.0]	
<b>Age greater than 65</b>				0.33
Yes	168 (51.2%)	150 (55.6%)	318 (53.2%)	
No	160 (48.8%)	120 (44.4%)	280 (46.8%)	
<b>Race</b>				0.66
American Indian, Alaskan Native	5 (1.5%)	6 (2.2%)	11 (1.8%)	
Asian	5 (1.5%)	4 (1.5%)	9 (1.5%)	
Black	14 (4.3%)	5 (1.9%)	19 (3.2%)	
Hawaiian, Pacific Islander	1 (0.3%)	1 (0.4%)	2 (0.3%)	
Other	11 (3.4%)	6 (2.2%)	17 (2.8%)	
White	278 (84.8%)	214 (79.3%)	492 (82.3%)	
Missing	14 (4.3%)	34 (12.6%)	48 (8.0%)	
<b>Ethnicity</b>				0.58
Hispanic	129 (39.3%)	102 (37.8%)	231 (38.6%)	
Non-Hispanic	188 (57.3%)	133 (49.3%)	321 (53.7%)	
Missing	11 (3.4%)	35 (13.0%)	46 (7.7%)	
<b>BMI</b>				<0.01
30 or greater	52 (15.9%)	24 (8.9%)	76 (12.7%)	
35 or greater	35 (10.7%)	11 (4.1%)	46 (7.7%)	
<b>Hypertension</b>				<0.01
Yes	176 (53.7%)	55 (20.4%)	231 (38.6%)	
No	152 (46.3%)	215 (79.6%)	367 (61.4%)	
<b>Chronic Kidney Disease</b>				0.22
Yes	19 (5.8%)	9 (3.3%)	28 (4.7%)	
No	309 (94.2%)	261 (96.7%)	570 (95.3%)	
<b>Cardiovascular Disease</b>				<0.01
Yes	71 (21.6%)	20 (7.4%)	91 (15.2%)	
No	257 (78.4%)	250 (92.6%)	507 (84.8%)	
<b>COVID-related ED visit or Admission within 30 days</b>				<0.01
Yes	39 (11.9%)	5 (1.9%)	44 (7.4%)	
No	289 (88.1%)	265 (98.1%)	554 (92.6%)	

383

384

385 **Table 3. Risk of COVID-19-related hospitalization or emergency department visit within 30 days**

386 *of SARS-CoV-2-positive viral test. \*p<0.05. Abbreviations: CI, confidence interval; mAb,*

387 *monoclonal antibody; OR, odds ratio.*

	<b>Unadjusted</b>		<b>Adjusted</b>	
	OR	[95% CI]	OR	[95% CI]
(Intercept)			0.05	[0.02, 0.12]
<b>Gender</b>				
Female	1.00	[0.54, 1.93]	0.88	[0.44, 1.78]
Male	<i>Reference</i>		<i>Reference</i>	
<b>Age (years)</b>				
≤64	<i>Reference</i>		<i>Reference</i>	
>65	1.06	[0.57, 1.99]	2.10	[0.97, 4.77]
<b>Race</b>				
Black	1.60	[0.23, 5.90]	1.2	[0.17, 5.12]
White	<i>Reference</i>		<i>Reference</i>	
Other	0.36	[0.02, 1.71]	0.35	[0.02, 1.79]
Unknown	0.29	[0.01, 1.35]	0.54	[0.03, 2.87]
<b>Ethnicity</b>				
Hispanic	1.50	[0.80, 2.78]	1.66	[0.84, 3.32]
Non-Hispanic	<i>Reference</i>		<i>Reference</i>	
<b>Body Mass Index</b>				
<30	<i>Reference</i>		<i>Reference</i>	
≥30 and <35	1.61	[0.67, 3.46]	1.98	[0.76, 4.76]
≥35	4.95	[2.21, 10.5]*	6.44	[2.48, 16.71]*
<b>Comorbidities</b>				
Hypertension	2.22	[1.19, 4.19]*	1.37	[0.67, 2.81]
Chronic Kidney Disease	1.61	[0.36, 4.89]	1.15	[0.25, 3.79]
Cardiovascular Disease	1.73	[0.78, 3.54]	1.07	[0.45, 2.40]
<b>mAb Treatment</b>	0.14	[0.05, 0.34]*	0.18	[0.06, 0.44]*

388

389

390 **Supplemental Table. STROBE Statement**

	<b>Item No</b>	<b>Recommendation</b>	<b>Page No</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract, (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg 3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pgs 4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Pgs 5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pgs 5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	Pg 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pgs 6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pgs 6-7
Bias	9	Describe any efforts to address potential sources of bias	Pg 6
Study size	10	Explain how the study size was arrived at	Pgs 6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pgs 7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	Pg 8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Pg 8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	Pg 8

Outcome data	15*	Report numbers of outcome events or summary measures over time	Pg 9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Pg 9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Pgs 9-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg 11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pgs 9, 12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg 12

391